HOVANA

HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new class of genomic medicines that selectively block oncogene translation in hard-to-treat tumors.

The company is led by a team whose work has generated 12 registered therapeutics, and founded by pioneers in cellular reprogramming at Harvard Stem Cell Institute (HSCI) and Boston Children’s Hospital. HOVANA combines expertise across functional genomics, structural chemistry and predictive diagnostics to drug a previously untapped layer of biological regulation in complex, multigenic diseases like cancer.

Hovana’s approach provides an opportunity to identify potent small molecule modulators of tRNA-Regulating Proteins (TRPs) — key molecular drivers of oncogenic translation — with a goal to advance a pipeline of precision medicines with disease-modifying potential and long-lasting efficacy.

The company was founded in 2023 and is based in Cambridge, MA.

Subscribe for alerts on new companies featured on Startups.Bio

Archon Biosciences
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Cytospire Therapeutics
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
This Week in Biotech Venture Capital
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …

View all recently featured startups

Tags: